Towards Healthcare
Bronchitis Treatment Market Size Surges USD 7.21 Billion in 2025

Bronchitis Treatment Market Accelerated by North America 43% Share, New Drug Launches & AI Tools in 2025

Projections indicate that, the global bronchitis treatment market will increase from USD 6.85 billion in 2024 to USD 11.45 billion by 2034, experiencing a CAGR of 5.28% over the next 10 years. The market is driven by growing COPD cases (due to air pollution, smoking, and an aging population), along with rising public awareness about respiratory health and treatment. Whereas, North America dominated the bronchitis treatment market due to the increasingly high COPD prevalence, advanced diagnostic capabilities, and broad use of combination inhalers.

Category: Therapeutic Area Insight Code: 5832 Format: PDF / PPT / Excel

Bronchitis Treatment Market Size, Segmental Insights with Key Players

The global bronchitis treatment market size is calculated at US$ 6.85 in 2024, grew to US$ 7.21 billion in 2025, and is projected to reach around US$ 11.45 billion by 2034. The market is expanding at a CAGR of 5.28% between 2025 and 2034.

The global bronchitis treatment market has been expanding with the influence of several factors like both acute and chronic bronchitis prone to COPD cases, developing urbanization with raised smoking, industrial development with chemical emission, and leading to increased air pollution. These factors are widely in demand for bronchitis treatment, including long-acting bronchodilators, robust inhalers. Many opportunities are emerging for the future globe, such as advancements in targeted therapies, nebulizers, inhalers, and other drug formulations with an enhanced drug delivery approach.

Bronchitis Treatment Market Size 2024 - 2034

Key Takeaways

  • Bronchitis treatment market to cross USD 6.85 billion in 2024.
  • Market projected at USD 11.45 billion by 2034.
  • CAGR of 5.28% expected in between 2025 to 2034.
  • North America dominated the global bronchitis treatment market with 43% revenue share in 2024.
  • Asia Pacific is expected to be the fastest-growing region during 2025-2034. 
  • By disease type, the acute bronchitis segment held a major share, 59% of the market in 2024.
  • By disease type, the chronic bronchitis (COPD-related) segment is expected to register the fastest CAGR in the upcoming years.
  • By treatment type, the drug therapy segment led the market with a nearly 66% revenue share in 2024.
  • By treatment type, the pulmonary rehabilitation segment is expected to expand at the fastest CAGR during the forecast period.
  • By drug class, the bronchodilators segment was dominant (34%) in the global bronchitis treatment market in 2024.
  • By drug class, the anti-inflammatories segment is expected to grow rapidly over the projected period.
  • By distribution channel, the retail pharmacies segment held the dominating revenue share of 45% in the market in 2024.
  • By distribution channel, the online pharmacies segment is expected to be the fastest-growing in the studied years.
  • By end user, the hospitals & clinics segment led with 51% share of the market in 2024.
  • By end user, the homecare settings segment is expected to grow at the fastest CAGR during 2025-2034.

Key Metrics and Overview

Metric Details
Market Size in 2025 USD 7.21 Billion
Projected Market Size in 2034 USD 11.45 Billion
CAGR (2025 - 2034) 5.28%
Leading Region North America share by 43%
Market Segmentation By Disease Type, By Treatment Type, By Drug Class, By Distribution Channel, By End User, By Region
Top Key Players GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Mylan N.V. (part of Viatris), Sanofi S.A., Cipla Ltd., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Zambon S.p.A., Merck & Co., Inc., Vertex Pharmaceuticals Inc., Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Aurobindo Pharma Ltd., Otsuka Pharmaceutical Co., Ltd., Viatris Inc.

Market Overview: Immense Focus on COPD Treatment

The bronchitis treatment market comprises pharmaceutical, supportive care, and preventive therapies used to manage acute and chronic bronchitis, an inflammatory condition of the bronchial tubes that causes coughing, mucus production, and respiratory discomfort. Acute bronchitis is often viral and self-limiting, while chronic bronchitis, a key form of chronic obstructive pulmonary disease (COPD), requires long-term treatment. The market is driven by air pollution, smoking, respiratory infections, and the rising prevalence of chronic respiratory disorders, particularly among aging populations. Recently, this treatment has focused on an innovative minimally invasive procedure for chronic bronchitis called RejuvenAir® metered cryospray.

  • In May 2025, Thirona, a global leader in AI-powered lung image analysis, partnered with the COPD Foundation to expand a research study on the COPDGene cohort involving more than 10,000 research volunteers. (Source - Ioplus)
  • In May 2025, the Abu Dhabi Public Health Centre (ADPHC) and AstraZeneca FZ LLC (AstraZeneca) collaborated to accelerate public health initiatives and enhance outcomes for patients with COPD in Abu Dhabi Emirate (Source - Zawya)
  • In September 2024, CSA Medical Inc., developer of The RejuvenAir® System, an innovative medical device, raised $53 million in series D financing to assist PMA of the RejuvenAir system. (Source - PR newswire)

How is AI Powering the Bronchitis Treatment Market?

In 2025, AI algorithms are broadly employed in bronchitis conditions to analyze medical images (like chest X-rays) and patient data to optimize the precision and pace of the diagnosis with enabling differentiation from other respiratory conditions. Besides this, AI helps to represent predictive modeling by identifying high-risk individuals, allowing proactive interventions and public health responses. Moreover, for the development of personalized treatment, AI uses genetic information, medical history, and treatment responses to increase strategies for the most efficient treatment.

Market Dynamics

Driver

Growing COPD Cases and Public Awareness

The major drivers in the bronchitis treatment market are increased incidences of both acute and chronic bronchitis, especially in COPD, fueled by factors like smoking, air pollution, and an aging population. Along with this, governments and healthcare organizations are emphasizing public awareness about bronchitis and its management with rising expenditure on healthcare, including respiratory illnesses such as bronchitis, which propels market growth.

Number of COPD Cases Around the World-01

Restraint

Delayed Diagnosis and Antibiotic Resistance

As in bronchitis, early and accurate detection plays a crucial role; sometimes symptoms can lead to delayed diagnosis or misdiagnosis, ultimately affecting to results and probably raise an unessential use of drugs. Also, in some cases, overuse and misuse of antibiotics may generate antibiotic resistance, which develops challenges to treat bacterial infection linked with bronchitis.

Opportunity

Advancements in Novel Therapies and Accelerating Digitalization

In the bronchitis treatment market, numerous opportunities are rising, including the development and utilization of novel inhalation devices and drug formulations with a focus on target-specific pathways or mechanisms in bronchitis. Furthermore, in the upcoming generation, grasping digitalization approaches such as telehealth platforms for remote diagnosis, monitoring, and patient involvement, to escalate access to care and treatment adoption.

Segmental Insights

Why did the Acute Bronchitis Segment Dominate the Market in 2024?

By disease type, the acute bronchitis segment led the bronchitis treatment market in 2024, due to contributing factors like rising air pollution, environmental factors including season changes, as well as increasing habituation of smoking in the growing population. Along with this, the increasing geriatric population is highly prone to the development of acute bronchitis conditions are fueling demand for effective bronchitis treatments.

However, the chronic bronchitis (COPD-related) segment is predicted to grow rapidly in the studied years. The segment is driven by accelerating tobacco consumption, rising occupational hazards like dust, fumes, and chemicals in certain industries, as well as other factors, including age, genetics, respiratory infections during childhood, and conditions like asthma and sleep apnea.

Which Treatment Type Dominated the Bronchitis Treatment Market in 2024?

The drug therapy segment was dominant with 66% revenue share in 2024. Increasing prevalence of bronchitis, COPD, and smoking, particularly in urban areas, is majorly fueling demand for this segment. Also, these drug therapies enable symptom management such as cough, inflammation, and mucus production, by providing combined inhalers like bronchodilators and corticosteroids, and mucolytics, are support overall market growth.

By treatment type, the pulmonary rehabilitation segment is seen to grow fastest, due to its efficiency in enhancing exercise capacity, decreasing dyspnea, boosting psychological well-being, and lowering healthcare utilization. Moreover, their programs encompass exercise training, education, and self-management interventions, which are significant for managing chronic respiratory diseases and promoting long-term health-enhancing behaviors.

How did the Bronchodilators Segment Lead the Market in 2024?

By drug class, the bronchodilators segment held a 34% in the global bronchitis treatment market in 2024. Specific bronchodilators such as short-acting beta-2 agonists, inhaled corticosteroids, and long-acting beta-2 agonists are widely employed in increasing incidences of acute and COPD bronchitis, with raised efficacy, safety, and reduced side effects, are ultimately impact the segment expansion.

And the anti-inflammatories segment is anticipated to show the fastest growth, due to the rising burden of both acute and chronic bronchitis with COPD, and enhanced morbidity and mortality rates. Whereas, this class of drug provides a combination therapy including bronchodilators and mucolytics, further boosting demand within the overall market. 

What made the Retail Pharmacies Segment Dominant in the Bronchitis Treatment Market in 2024?

By distribution channel, the retail pharmacies segment captured a major share of the market in 2024. The segment is fueled by its convenient access to a range of over-the-counter (OTC) drugs, such as cough suppressants (dextromethorphan), expectorants (guaifenesin), and pain relievers (ibuprofen, acetaminophen), which are highly used to treat bronchitis.

On the other hand, the online pharmacies segment is estimated to grow fastest with its major advantages like convenience, accessibility, and the raised adoption of digital healthcare, especially among younger demographics and COVID-era trends. As well as these pharmacies allow cost-effective shopping with protected privacy and confidentiality about sensitive cases is accelerating its adoption over the globe.

By end user, Which Segment Showed Dominance in the Bronchitis Treatment Market in 2024?

The hospitals & clinics segment dominated the market, due to the availability of advanced treatments, particularly personalized medicines and advanced therapies, which have assisted in accelerating bronchitis cases. Apart from this, hospitals and clinics possess developed diagnostic tools and approaches that are supporting to differentiating between acute and chronic bronchitis, guiding accurate treatment strategies within healthcare facilities.

Moreover, the homecare settings segment is estimated to expand rapidly during the forecast period. Widely beneficial for the geriatric population with major bronchitis conditions, with ease of operation in remote mode, along with technological innovations in respiratory devices, including nebulizers and pulse oximeters, are making it more accessible and effective to manage bronchitis symptoms at home.

Regional Insights

Bronchitis Treatment Market Share, By Region, 2024 (%)

What made North America dominate the Market in 2024?

North America dominated the global bronchitis treatment market share by 43% in 2024, due to driven by growing high COPD prevalence, advanced diagnostic capabilities, and widespread use of combination inhalers, with raised demand for effective treatment. As well as, this region’s governments and private sectors are actively encouraging major investments in healthcare, including bronchitis treatments is driving the market growth.

The U.S. Bronchitis Treatment Market Trends

In the US, significantly contributing factors are a growing aging population with respiratory diseases like asthma and bronchitis, with an accelerating focus on the development of the healthcare systems.

For instance,

  • In September 2024, DirectRx, a specialty pharmacy for people with chronic health disorders, announced as the part of the exclusive U.S. pharmacy network distributing Ohtuvayre (ensifentrine), a newly approved therapy for chronic obstructive pulmonary disease (COPD).
  • In September 2023, Lupin, a pharmaceutical company, partnered with Mark Cuban and the COPD Foundation to enhance access to COPD medication in the US (Source - Business today)

The Canada Bronchitis Treatment Market Trends

Canada’s government is stepping towards initiatives like public health campaigns and programs focused on accelerating awareness about respiratory health and promoting early diagnosis and treatment of bronchitis. As well as, adoption of digital healthcare, such as telemedicine, is propelling the market growth in this region.

For this market,

  • In April 2025, Walmart Canada launched in-store pharmacy clinics in Canada, increasing Canadians' access to affordable healthcare. (Source - Newswire)

Progressing Urbanization and Rising Population are Driving Asia Pacific

In the upcoming era, the Asia Pacific is estimated to grow at a rapid CAGR in the global bronchitis treatment market, due to developing countries like China and India are experiencing major urbanization, including the development of a large number of industries with generating huge air pollution by hazardous chemical emissions. Besides this, another concern is the growing population, which includes more geriatric people who are highly prone to the emergence of respiratory diseases like bronchitis are widely adopting or need effective bronchitis treatment is ultimately expanding the market.

The India Bronchitis Treatment Market Trends

Along with an aging population, air pollution and smoking, rising diagnoses, and awareness about bronchitis and its symptoms are boosting the market growth in India. Also, the environmental factors like seasonal changes are developing various respiratory concerns are raising demand for efficient treatment.

For this market,

  • In March 2025, Aerogen, a global provider of acute-care aerosol drug delivery solutions, inaugurated its India headquarters in the National Capital Territory of Delhi.  (Source - Express healthcare)

The China Bronchitis Treatment Market Trends

China has been experiencing major growth due to a significant population of smokers who are facing risks of developing bronchitis and COPD (Chronic Obstructive Pulmonary Disease), resulting in an enormous demand for treatment. Although consumers are highly adopting OTC medications with enhanced awareness about respiratory health is accelerating the demand for cough and bronchitis treatment.

For instance,

  • In June 2025, Lupin Ltd. agreed with Sino Universal Pharmaceuticals (SUP) to introduce Tiotropium Dry Powder Inhaler (DPI), 18 mcg per capsule, in the Chinese market. (Source - Business standard)

Increasing Prevalence of COPD and Healthcare Spending are Driving Europe

Primarily, Europe is facing a significant growth in the market, with escalating cases of COPD derived from chronic bronchitis are immensely demanding for bronchitis treatment, resulting in market growth. Besides this, European governments and private firms are mainly investing in healthcare systems to boost the awareness and adoption of novel respiratory treatments among the people.

The UK Bronchitis Treatment Market Trends

The UK, with advanced healthcare infrastructures possessing well-developed facilities like advanced diagnostic tools and medical devices, is boosting the market growth. Additionally, continuous R&D activities for novel and optimized respiratory therapies for bronchitis are also generating chances of market expansion.

For this market,

  • In May 2025, Chiesi UK and Ireland and Wirral Primary Care Collaborative (WPCC) are allied to unveil COMET, a programme designed to accelerate early diagnosis and management of chronic obstructive pulmonary disease (COPD) in the Wirral. (Source - Pharma times)

The French healthcare system is widely covering and focusing on respiratory disease management, as well as raising breakthroughs in drug formulations, such as cough remedies, combination therapies, and marketing strategies by pharmaceutical companies also play a crucial role in market expansion.

Top Companies in the Bronchitis Treatment Market

Bronchitis Treatment Market Companies

  • GlaxoSmithKline plc
  • AstraZeneca plc 
  • Boehringer Ingelheim GmbH 
  • Teva Pharmaceutical Industries Ltd. 
  • Novartis AG
  • Pfizer Inc.
  • Mylan N.V. (part of Viatris)
  • Sanofi S.A.
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Chiesi Farmaceutici S.p.A. 
  • Dr. Reddy’s Laboratories
  • Zambon S.p.A.
  • Merck & Co., Inc.
  • Vertex Pharmaceuticals Inc.
  • Lupin Pharmaceuticals 
  • Glenmark Pharmaceuticals 
  • Aurobindo Pharma Ltd. 
  • Otsuka Pharmaceutical Co., Ltd.
  • Viatris Inc.

Latest Announcements by Industry Leaders

  • In May 2025, Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced an alliance with Sanofi and Regeneron to improve an AI-powered workflow solution for chronic obstructive pulmonary disease (COPD). Chris Mansi, MD, CEO and co-founder of Viz.ai, stated that this approach will empower healthcare providers to convey data-driven, guideline-directed care that majorly impacts patient outcomes.
  • In October 2024, Honeywell announced a long-term supply agreement with DevPro Biopharma to develop a respiratory inhaler. DevPro CEO and Co-Founder Colin Reisner commented that this collaboration will enhance the development of low-carbon propellant alternatives. (Source - Pharmaceutical manufacturer)

 What are the Recent Developments in the Bronchitis Treatment Market?

  • In June 2025, the Pondicherry Institute of Medical Sciences (PIMS) launched a state-of-the-art Medical ICU and introduced a new biological therapy for asthma patients. (Source - The Hindu)
  • In May 2025, Huma, a London-based healthtech unicorn, acquired US respiratory health startup Aluna, and a new strategic partnership with Eckuity Capital to assist a broader M&A strategy. (Source - Tech.eu)
  • In January 2025, Cipla, a pharmaceutical company, unveiled the CipAir mobile app for first-line asthma screening in India. (Source - Business standard)
  • In November 2024, AstraZeneca, a MNC pharmaceutical company, announced the introduction of the COPD inhaler Breztri Aerosphere in India in January 2025. (Source -  Cnbctv18)

Segments Covered in the Report

By Disease Type 

  • Acute Bronchitis
    • Viral Infections (e.g., influenza, rhinovirus)
    • Bacterial Infections (e.g., Mycoplasma, Bordetella pertussis)
  • Chronic Bronchitis (COPD-related)
    • Smoking-induced 
    • Occupational exposure 
    • Environmental pollutants

 By Treatment Type 

  • Drug Therapy
  • Bronchodilators (e.g., salbutamol)
    • Corticosteroids (e.g., prednisone, fluticasone)
    • Antibiotics (for bacterial cases)
    • Antitussives & Expectorants (e.g., dextromethorphan, guaifenesin)
    • Antivirals (in some acute cases)
  • Oxygen Therapy
  • Pulmonary Rehabilitation
  • Humidifiers & Nebulizers
  • Lifestyle Modification & Smoking Cessation

By Drug Class 

  • Bronchodilators
    • Beta-2 Agonists
    • Anticholinergics
  • Corticosteroids 
  • Mucolytics
  • Antibiotics 
  • Anti-inflammatories

By Distribution Channel

  • Retail Pharmacies 
  • Hospital Pharmacies 
  • Online Pharmacies 

By End User 

  • Hospitals & Clinics  
  • Ambulatory Care Centers  
  • Homecare Settings Shape, Picture  

By Region 

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Last Updated: 09 July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

Meet the Team

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations.

Learn more about Kesiya Chacko

Aditi Shivarkar, with over 14 years of experience in consumer goods, leads research at Towards Consumer Goods, ensuring precise, actionable insights on trends, consumer preferences, and sustainable packaging for businesses.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

The bronchitis treatment market is projected to reach USD 11.45 billion by 2034, growing at a CAGR of 5.28% from 2024 to 2034.

North America is currently leading the bronchitis treatment market due to increasing high COPD prevalence, advanced diagnostic capabilities, and widespread use of combination inhalers.

The bronchitis treatment market includes 6 segments such as by disease type, by treatment type, by drug class, by distribution channel, by end-user, and by region.

Some key players include Pfizer, Sanofi, AstraZeneca, Sanofi, Cipla, and Novartis.

Key trends include rising demand for bronchitis treatment and personalized medicine, growth in programs related to respiratory health and treatment, and innovation in therapies and medical devices.

The potential future developments in bronchitis treatment are gene therapy, immunotherapy, and novel drug delivery systems.

Dextromethorphan (Robitussin, Delsym) is the most commonly used and best OTC cough medication for acute bronchitis.

The brand names of bronchodilator inhalers are salmeterol (brand names Serevent® and Neovent®) and formoterol (brand names Atimos®, Foradil®, and Oxis®).

NIH.GOV, US FDA.GOV, GOV.UK, CDC.GOV, HEALTHDIRECT.GOV, MEDLINEPLUS.GOV